Edwards Lifesciences (EW) Tops Q4 EPS by 3c, Offers Q1 Guidance

Go back to Edwards Lifesciences (EW) Tops Q4 EPS by 3c, Offers Q1 Guidance

Northland Capital Remains Positive on Edwards Lifesciences (EW) Long-Term Outlook

February 2, 2017 12:50 PM EST

Northland Capital Markets analyst Suraj Kalia is sticking with her Outperform rating and $105 price target on Edwards Lifesciences (NYSE: EW) even though the company is hard time meeting lofty Street expectations.

Kalia commented, "Q4-16 revs @ $768M > consensus @ $758M & our estimate @ $763M. GAAP EPS @ $0.73 > our estimate @ $0.71 &... More

Leerink Partners Downgrades Edwards Lifesciences (EW) to Market Perform

February 2, 2017 9:34 AM EST

Leerink Partners downgraded Edwards Lifesciences (NYSE: EW) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.

Shares of Edwards Lifesciences closed at $98.02 yesterday.

... More